Pfizer Inc. (PFE) saw a nearly 3% drop in share value on Thursday after announcing the departure of Chief Financial Officer Dave Denton, effective August 15. Denton is leaving for a “professional opportunity outside of the pharmaceutical industry” in consumer goods, prompting the company to start a search for a permanent successor. Cecile Guega, currently senior vice president of finance, will take over as interim CFO on August 16.
Denton’s resignation coincides with Pfizer’s ongoing post-pandemic transformation strategy, which he has been overseeing since joining in May 2022. The company has maintained its 2026 financial guidance, expecting total revenues between $59.5 billion and $62.5 billion, reflecting a decline from 2025 revenues of $62.6 billion due to diminishing COVID-related sales and an impending patent cliff.
In conjunction with lower expected revenues, Pfizer forecasts adjusted earnings per share (EPS) for 2026 to be in the range of $2.80 to $3.00, compared to $3.22 in 2025, impacted by acquisitions, reduced COVID revenues, and increased taxes.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
